Health, Fitness & Food

Gary Gottlieb is in a prime spot to see how technology companies are shaking up health care. A trained psychiatrist who previously ran Partners Healthcare in Boston, one of the largest hospitals in the country, Gottlieb has spent the past three years working in venture capital, tracking how emerging start-ups and big tech companies are
0 Comments
Health and Human Services Secretary Alex Azar had a stern warning for the pharmaceutical industry on Friday, a day after the Trump administration proposed a plan to change the way Medicare pays for certain expensive drugs. Speaking from the Brookings Institution in Washington, Azar said Big Pharma cannot stand by and defend the status quo
0 Comments
Regulators are considering prohibiting some e-cigarette sales in convenience stores and confining them to vape shops, Food and Drug Administration Commissioner Scott Gottlieb told CNBC on Friday. High school e-cigarette use surged 77 percent last year, Gottlieb said in an interview on “Squawk Box,” citing preliminary figures from the federal Youth Tobacco Survey. Middle school
0 Comments
More high school kids are smoking cigarettes as vaping surges, reversing a two-decade-long decline. Last year, 8.1 percent of high school students reported smoking cigarettes, up from 7.6 percent in 2016, according to federal health officials, who asked not to be named because the data haven’t been publicly released. The increase is not statistically significant,
0 Comments
AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company. Tuesday’s agreement is a coup for Innate — run by former AstraZeneca executive Mondher Mahjoubi — which gains rights to sell AstraZeneca’s newly approved rare blood
0 Comments
When pharma giant Pfizer announced in January it planned to shut down early- and mid-stage neuroscience drug development, it was another blow to a field already in a defensive crouch. Diseases of the central nervous system — from Alzheimer’s to Parkinson’s to Lou Gehrig’s disease — have been incredibly difficult for drug developers to crack,
0 Comments